Germany
Japan
United Kingdom
China
Antibodies
View as table Download
Mouse Monoclonal Cystatin C Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal H-FABP Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal H-FABP Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 380.00
4 Weeks
Mouse Monoclonal Ferritin Light Chain Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal Leptin Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal Leptin Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal NGAL Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal Human Serum Albumin Antibody
| Applications | ELISA, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal Cystatin C Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD52 (Clone Campath-1H)
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD52 (Clone Campath-1H)
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-D-Dimer (Clone 3B6)
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-D-Dimer (Clone 3B6)
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-Insulin Receptor alpha (Clone 83-14)
| Applications | ELISA, IF, IHC, IP, WB |
| Reactivities | Bovine, Human, Sheep, Pig |
| Conjugation | Unconjugated |
Recombinant Anti-Insulin Receptor alpha (Clone 83-14)
| Applications | ELISA, IF, IHC, IP, WB |
| Reactivities | Bovine, Human, Sheep, Pig |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Insulin receptor alpha (Clone 83-7)
| Applications | ELISA, IHC, IP |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-Insulin receptor alpha (Clone 83-7)
| Applications | ELISA, IHC, IP |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-IL-18 (Clone 125-2H)
| Applications | ELISA, IF, IP |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-IL-18 (Clone 125-2H)
| Applications | ELISA, IF, IP |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-p53 (Clone PAb421)
| Applications | ELISA, IF, IHC, IP, WB |
| Reactivities | Human, Monkey, Mouse, Rabbit, Rat |
| Conjugation | Unconjugated |
Recombinant Anti-p53 (Clone PAb421)
| Applications | ELISA, IF, IHC, IP, WB |
| Reactivities | Human, Monkey, Mouse, Rabbit, Rat |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD52 (Clone YTH 34.5-G2b (Campath-1G))
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD52 (Clone YTH 34.5-G2b (Campath-1G))
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD52 (Clone YTH 34.5-G2b (Campath-1G))
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
Recombinant Anti-VAP-1 (Clone TK8-14)
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-VAP-1 (Clone TK8-14)
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-VAP-1 (Clone 2D10)
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-VAP-1 (Clone 2D10)
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 1 (Clone E6)
| Applications | ELISA, IHC |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 1 (Clone E6)
| Applications | ELISA, IHC |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 2 (Clone B6)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 2 (Clone B6)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 2 (Clone B9)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 2 (Clone B9)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-IFN gamma (Clone D9D10)
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-IFN gamma (Clone D9D10)
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-MUC1 (Clone SM3)
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-MUC1 (Clone SM3)
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Active filters
Category
- Antibodies
Reactivities
- Human
Clonalities
- Monoclonal
Assay Types
- Indirect
Filter by
Target Symbol
- MAPT (24)
- MUC1 (10)
- TNF (9)
- CCR5 (8)
- CD4 (7)
- EGFR (7)
- CD52 (6)
- MSLN (6)
- VEGFA (6)
- CD80 (5)
- ERBB2 (5)
- H3-3A (5)
- AOC3 (4)
- CD44 (4)
- FN1 (4)
- IL2RA (4)
- INSR (4)
- ITGB2 (4)
- NOTCH2 (4)
- PXN (4)
- TNFRSF8 (4)
- APP (3)
- CD40 (3)
- ITGA5 (3)
- LEY (3)
- SLC3A2 (3)
- TYRP1 (3)
- ACKR1 (2)
- ADRB2 (2)
- AGER (2)
- AKT1 (2)
- ALBUMIN (2)
- C3AR1 (2)
- C5AR1 (2)
- CD1A (2)
- CD28 (2)
- CD40LG (2)
- CD55 (2)
- CD74 (2)
- CD81 (2)
- CR1 (2)
- CYSTATIN C (2)
- DDR1 (2)
- EDAR (2)
- EPCAM (2)
- EPHA2 (2)
- FABP3 (2)
- FAS (2)
- FCAR (2)
- FCGR2A (2)
- FGA (2)
- FGB (2)
- GM2 (2)
- GPR119 (2)
- GYPA (2)
- H3 (2)
- H4 (2)
- IFNG (2)
- IGE (2)
- IGM (2)
- IL10 (2)
- IL16 (2)
- IL18 (2)
- IL2 (2)
- IL5 (2)
- IL6R (2)
- IL7R (2)
- IL9 (2)
- ITGA2B (2)
- ITGA4 (2)
- ITGAX (2)
- LEP (2)
- LTA (2)
- NCAM1 (2)
- NOTCH1 (2)
- NTRK1 (2)
- PRDX4 (2)
- PROC (2)
- RAP (2)
- RHO (2)
- SEPTIN5 (2)
- SIRPG (2)
- SNAP25 (2)
- TF (2)
- TGFA (2)
- TNFRSF10B (2)
- TNFRSF9 (2)
- TP53 (2)
- TRAC (2)
- TSPAN1 (2)
- TUBA1A (2)
- TUBB3 (2)
- XPNPEP1 (2)
- ADORA2A (1)
- ANXA4 (1)
- BRD4 (1)
- BSG (1)
- CALR (1)
- CBX1 (1)
- CBX2 (1)
Applications
Antibody Hosts
Isotypes
Conjugates
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (40)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (9)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
Families
Pathways
- Alzheimer's disease (24)
- MAPK signaling pathway (24)
- Cytokine-cytokine receptor interaction (3)
- Adipocytokine signaling pathway (2)
- Jak-STAT signaling pathway (2)
- Neuroactive ligand-receptor interaction (2)
- PPAR signaling pathway (2)
- Bladder cancer (1)
- Chemokine signaling pathway (1)
- Epithelial cell signaling in Helicobacter pylori infection (1)
- NOD-like receptor signaling pathway (1)
- Pathways in cancer (1)
- RIG-I-like receptor signaling pathway (1)
- Toll-like receptor signaling pathway (1)